Nygren PJ, Bouhlal JOV, Jokinen E, Forstén S, Laajala E, Dias DAA, Adnan Awad S, Ianevski A, Klievink J, Lähteenmäki H, Kuusanmäki H, Myllymäki M, Kasanen T, Saeed K, Lee DA, Flagship I, Hjorth-Hansen H, Aittokallio T, Dufva O, Mustjoki S (2025)
High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia
Blood (in press)
DOI 10.1182/blood.2024025286, PubMed 39792962

Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L et al. (2024)
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
Hemasphere, 8 (12), e70001
DOI 10.1002/hem3.70001, PubMed 39619245

Tanoli Z, Schulman A, Aittokallio T (2024)
Validation guidelines for drug-target prediction methods
Expert Opin Drug Discov, 20 (1), 31-45
DOI 10.1080/17460441.2024.2430955, PubMed 39568436